Fractyl Hit Its Endpoint and the Market Took 76% of the Company Away in Nine Days
A p=0.0023 win, a 45% workforce cut, a gene therapy abandoned, and a $10.8 million market cap — the market's verdict on Revita's 6-month data.
GUTS · Earnings Call · 2026-11-12
A win the tape refused to price
Fractyl's third quarter call opened with a number that should have been a floor under the equity: “the study met its 6-month co-primary endpoint with high statistical significance, p-value of 0.0023” — Harith Rajagopalan, Chief Executive Officer · 2026-11-12. REMAIN-1 is not a soft study — 308 patients in the modified intent-to-treat population, randomized 2:1, double-blind against a sham procedure, driven to at least 15% weight loss on high-dose tirzepatide, then cut off the drug outright. Revita patients retained roughly 80% of what they had lost. The tape read the same readout and reached the opposite conclusion. GUTS is down 90.5% across the last ninety sessions, and the shape is brutal rather than gradual: a -76% collapse compressed into nine trading days, bracketing the October data. Against a whole-history peak of $154.20 in February 2024 the drawdown is -99.4%, leaving a market capitalisation near $10.8 million. That is not a discount for disappointment. It is a price that treats the equity as a stub option on a 2028 launch. So the interesting question is not whether the primary endpoint hit. It did. The question is what the buyers saw in the details that the headline obscured.The goalpost moves a third time
Ablation length has been the connective tissue of this story for four quarters and it has now been re-specified again. On the March 2026 call the standard was declared settled:Analysts on that call were visibly surprised the parameter had ever been discretionary at all. Six months later the operative number on the Q3 call is 20-plus centimeters, with separation from sham now described as beginning at 12: “patients who reached 20 centimeters in the post-hoc analysis saw the greatest effect with no associated safety signal observed” — Harith Rajagopalan, Chief Executive Officer · 2026-11-12. Management frames the drift as evidence of longer ablations producing a dose response — which is a legitimate target-validation argument, and the top-ranked keyword of the quarter for good reason. But it also quietly converts the pivotal result into a post-hoc story: the cleanest efficacy lives in a subgroup defined after the data were unblinded, and the physical argument for the control arm being conservative cuts both ways. The other half of the machinery — “each additional 2 centimeters of ablation adds approximately 2 minutes to the procedure” — Harith Rajagopalan, Chief Executive Officer · 2026-11-12 — is reassuring for training and less reassuring for the idea that a real-world interventionalist will reliably deliver the full duodenum on day one.What is clear is that the ablation length for weight effects is greater than or equal to 16 centimeters. That will be our operating standard going forward and will be built into the key secondary endpoints in our pivotal study.
What Fractyl stopped saying
The loudest signal on this call is an absence. For the last four quarters gene therapy and RejuVa 001 sat in the top few company keywords — first dose timing, sentinel safety windows, Australian regulatory feedback, GIP-to-GLP potency ratios. As recently as the August call analysts were still asking about Rejuva data timing and where the first patients would be dosed. On the Q3 call Rejuva is mentioned once, in a sentence about discontinuing it, and not a single analyst asks a follow-up. The companion move is the 45% workforce reduction and the promise of cash spending halving to about $8 million a quarter by the end of Q2 2027. That is real discipline, and the CFO's framing is honest — “Beyond those milestones, we will need additional capital to bring Revita to market, and we will weigh every option with shareholder value in mind” — Lara Weber, Chief Financial Officer · 2026-11-12. But it also converts a two-pillar platform into a one-product company with a single binary readout and a financing gap immediately behind it. The fundamentals still on file are from the August 10-Q, and they already show the shape of the pivot: R&D down 35% year over year to $14 million and an operating loss of $19 million. Even with the cuts, runway stands at roughly 3.2 quarters.The demand story it is betting on
Fractyl's commercial case has genuinely sharpened, and it is the most company-unique thing in the transcript. The launch is not premised on converting GLP-1 patients at large; it is premised on a federal programme manufacturing the exact population Revita was studied in. The GLP 1 bridge programme is expected to put 4 to 5 million seniors on therapy by late 2027 — the year it expires — and management argues that every one of those patients is a future discontinuation. Layer on the proposed rapid reimbursement rule and its open question of an on-ramp for devices whose pivotal trials are already running, and a Category III code live from January 1 2027, and the payment architecture is more concrete than most pre-approval stories. The go-to-market is equally specific: metabolic interventionalist physicians inside the top 100 to 200 accredited bariatric centres, each already seeing over 2,000 GLP-1 patients a year. That is a plausible tens-of-reps launch. The counter-argument sits in the global tape, not in the transcript. Oral GLP-1 exposure has been one of the better-performing healthcare clusters over ninety days, and management's dismissal — a daily pill changes how you take the drug, not whether you want to stay on it — is a hypothesis, not a finding. If oral agents extend persistence, the off-ramp market shrinks precisely where Fractyl is aiming.Credibility is now the filed exhibit
What makes this call unusual is that the company invited shareholders to vote on questions for the first time, and the most-voted one was not about science:The CEO's answer — “Credibility is earned by doing what we say we will do” — Harith Rajagopalan, Chief Executive Officer · 2026-11-12 — is the right answer and also an uncomfortable one, because the de novo timeline has already softened. In August the close was “Top-line pivotal data in early Q4. Potential de novo submission late Q4.” — Harith Rajagopalan, Chief Executive Officer · 2026-08-10 Today the submission is something the company will begin late in Q4, with “completion with the full clinical package in the first quarter of 2027” — Harith Rajagopalan, Chief Executive Officer · 2026-11-12 — because the second co-primary endpoint reads out then and no pre-submission FDA meeting is planned. That is the real tension in the dossier. A statistically significant, sham-controlled performance goal win arrived, and the stock fell three-quarters in nine sessions, because the market simultaneously re-underwrote the effect size, the ablation dose, the loss of the second pillar, and the financing that has to happen before any of it converts. The de novo submission is now the only thing standing between a $10.8 million equity and its cash. Management calls this 'a moment Fractyl was built for'. The tape is calling it something else, and on the evidence of the last ninety days the tape is winning.what concrete steps are the Board and management taking to restore credibility with investors, including institutional investors?